Remove 2013 Remove Drug Development Remove Pharmaceutical Companies
article thumbnail

STAT+: AI drug firm Recursion moves from survival to industry domination

STAT

SALT LAKE CITY — On paper, Recursion Pharmaceuticals shouldn’t have worked. And the startup was based in Salt Lake City, Utah — an area better known for its ski slopes and connection to the Church of Jesus Christ of Latter-day Saints than drug development.  

article thumbnail

Using RWE in rare disease drug development: effective innovations with historical controls

European Pharmaceutical Review

Rare disease drug development poses unique challenges that can be overcome by using real-world evidence (RWE). These assessments often need to involve comparisons against multiple alternative therapies that would be impractical in the context of a clinical drug development. 2013 Oct; 48(10): 943–953. Thompson, LA.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AI-driven drug discovery, precision medicine, and sustainable manufacturing can redefine the pharma industry

Express Pharma

In India, pharmaceutical companies responded to global environmental concerns and government mandates by adopting greener manufacturing techniques. First, advanced research and development (R&D) and biologics will be critical. This transition will require substantial investments in several key areas.

article thumbnail

Patents: a necessary evil?

European Pharmaceutical Review

Patents are often described as the ‘lifeblood’ of pharmaceutical companies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment. 23 April 2013.

article thumbnail

Taming cardiovascular risk: the promise of LDL cholesterol lowering therapeutics

European Pharmaceutical Review

In this Q&A, he explores the trends and challenges within the cardiovascular treatment space, as well as clinical development of the company’s lead candidate obicetrapib, a cholesterol ester transfer protein (CETP) inhibitor for lowering low-density lipoprotein-cholesterol (LDL-C) and ultimately reducing cardiovascular risk.

article thumbnail

Race to the finish: pharma edges closer to approval with RSV vaccines

Pharmaceutical Technology

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

article thumbnail

Pharmaceutical microbiology: key developments 2022

European Pharmaceutical Review

” Tony Cundell: Contract manufacturing organisations (CROs), start-up companies, established pharmaceutical companies and regulatory agencies are having difficulty recruiting and retaining technically-trained personnel. He consults in the areas of microbial risk assessment, regulatory affairs and microbiological testing.

Vaccines 128